The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia

Douglas Gladstone, Amanda Blackford, Eunpi Cho, Lode Swinnen, Yvette Kasamon, Christopher Gocke, Constance A. Griffin, F Javier Bolanos Meade, Richard J Jones

Research output: Contribution to journalArticle

Abstract

Background: Most patients with CLL with a poor-risk cytogenetic profile have an unmutated IGHV sequence. Limited clinical information exists for patients with CLL who have a poor-risk cytogenetic profile and a mutated or good-risk IGHV status. We retrospectively screened all patients with CLL seen at our institution from 2006 onward who harbored a del(11q) or del(17p) CLL detected by fluorescence in situ hybridization (FISH) analysis for whom an IGHV analysis was requested. In 66 evaluable patients, 50 (76%) had an unmutated IGHV sequence. Thirty-nine patients (59%) had del(11q) and 27 patients (41%) had del(17p); no patient in this series had both del(11q) and del(17p). The patients' initial clinical presentations were similar in both mutational groups. Patients with an unmutated IGHV sequence were more likely to receive treatment and to have a shorter survival, with an estimated 3-year overall survival (OS) of 81% compared with 100% in the group with a mutated IGHV sequence (log rank, P = .06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis.

Original languageEnglish (US)
Pages (from-to)132-137
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Fluorescence In Situ Hybridization
Cytogenetics
Survival

Keywords

  • Clinical outcomes
  • CLL
  • del(11q)
  • del(17p)
  • IGHV

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. / Gladstone, Douglas; Blackford, Amanda; Cho, Eunpi; Swinnen, Lode; Kasamon, Yvette; Gocke, Christopher; Griffin, Constance A.; Bolanos Meade, F Javier; Jones, Richard J.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 12, No. 2, 04.2012, p. 132-137.

Research output: Contribution to journalArticle

@article{bbf5b6d601de47b79d3ccfd25ec0fc87,
title = "The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia",
abstract = "Background: Most patients with CLL with a poor-risk cytogenetic profile have an unmutated IGHV sequence. Limited clinical information exists for patients with CLL who have a poor-risk cytogenetic profile and a mutated or good-risk IGHV status. We retrospectively screened all patients with CLL seen at our institution from 2006 onward who harbored a del(11q) or del(17p) CLL detected by fluorescence in situ hybridization (FISH) analysis for whom an IGHV analysis was requested. In 66 evaluable patients, 50 (76{\%}) had an unmutated IGHV sequence. Thirty-nine patients (59{\%}) had del(11q) and 27 patients (41{\%}) had del(17p); no patient in this series had both del(11q) and del(17p). The patients' initial clinical presentations were similar in both mutational groups. Patients with an unmutated IGHV sequence were more likely to receive treatment and to have a shorter survival, with an estimated 3-year overall survival (OS) of 81{\%} compared with 100{\%} in the group with a mutated IGHV sequence (log rank, P = .06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis.",
keywords = "Clinical outcomes, CLL, del(11q), del(17p), IGHV",
author = "Douglas Gladstone and Amanda Blackford and Eunpi Cho and Lode Swinnen and Yvette Kasamon and Christopher Gocke and Griffin, {Constance A.} and {Bolanos Meade}, {F Javier} and Jones, {Richard J}",
year = "2012",
month = "4",
doi = "10.1016/j.clml.2011.12.005",
language = "English (US)",
volume = "12",
pages = "132--137",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia

AU - Gladstone, Douglas

AU - Blackford, Amanda

AU - Cho, Eunpi

AU - Swinnen, Lode

AU - Kasamon, Yvette

AU - Gocke, Christopher

AU - Griffin, Constance A.

AU - Bolanos Meade, F Javier

AU - Jones, Richard J

PY - 2012/4

Y1 - 2012/4

N2 - Background: Most patients with CLL with a poor-risk cytogenetic profile have an unmutated IGHV sequence. Limited clinical information exists for patients with CLL who have a poor-risk cytogenetic profile and a mutated or good-risk IGHV status. We retrospectively screened all patients with CLL seen at our institution from 2006 onward who harbored a del(11q) or del(17p) CLL detected by fluorescence in situ hybridization (FISH) analysis for whom an IGHV analysis was requested. In 66 evaluable patients, 50 (76%) had an unmutated IGHV sequence. Thirty-nine patients (59%) had del(11q) and 27 patients (41%) had del(17p); no patient in this series had both del(11q) and del(17p). The patients' initial clinical presentations were similar in both mutational groups. Patients with an unmutated IGHV sequence were more likely to receive treatment and to have a shorter survival, with an estimated 3-year overall survival (OS) of 81% compared with 100% in the group with a mutated IGHV sequence (log rank, P = .06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis.

AB - Background: Most patients with CLL with a poor-risk cytogenetic profile have an unmutated IGHV sequence. Limited clinical information exists for patients with CLL who have a poor-risk cytogenetic profile and a mutated or good-risk IGHV status. We retrospectively screened all patients with CLL seen at our institution from 2006 onward who harbored a del(11q) or del(17p) CLL detected by fluorescence in situ hybridization (FISH) analysis for whom an IGHV analysis was requested. In 66 evaluable patients, 50 (76%) had an unmutated IGHV sequence. Thirty-nine patients (59%) had del(11q) and 27 patients (41%) had del(17p); no patient in this series had both del(11q) and del(17p). The patients' initial clinical presentations were similar in both mutational groups. Patients with an unmutated IGHV sequence were more likely to receive treatment and to have a shorter survival, with an estimated 3-year overall survival (OS) of 81% compared with 100% in the group with a mutated IGHV sequence (log rank, P = .06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis.

KW - Clinical outcomes

KW - CLL

KW - del(11q)

KW - del(17p)

KW - IGHV

UR - http://www.scopus.com/inward/record.url?scp=84858959090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858959090&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.12.005

DO - 10.1016/j.clml.2011.12.005

M3 - Article

VL - 12

SP - 132

EP - 137

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -